Premature Structural Failure of Trifecta Bioprosthesis in Midterm Follow-up: A Single-Center Study

Area of Science:

• Cardiovascular Surgery
• Biomedical Engineering
• Prosthetic Valve Research

Background:

• A cluster of aortic bioprosthetic valve failures, primarily Trifecta prostheses, was noted at Southampton General Hospital.
• The study aimed to determine if this represented a significant failure rate for the Trifecta valve model or if selection bias was a factor.

Purpose of the Study:

• To assess the incidence of early structural failure in Trifecta bioprosthetic aortic valves.
• To compare the performance of Trifecta valves against other bioprosthetic models (Perimount, Perimount Magna Ease, Mitroflow).
• To identify potential patient-related or valve-related risk factors for early valve failure.

Main Methods:

• Retrospective evaluation of bioprosthetic aortic valve replacements performed between 2011 and 2016.
• Comparative analysis of Trifecta valves versus Perimount, Perimount Magna Ease, and Mitroflow valves.
• Analysis of risk factors for early structural failure in compromised valves.

Main Results:

• A total of 2807 bioprosthetic aortic valve replacements were analyzed.
• Twenty-four Trifecta valves (836 total) experienced premature structural failure, a significantly higher rate compared to Perimount (0/1031), Perimount Magna Ease (0/449), and Mitroflow (1/351).
• Failed Trifecta valves commonly presented with moderate to severe regurgitation (71%) at a mean of 4.5 years post-implantation, with no identified patient or valve-related causes.

Conclusions:

• The Trifecta bioprosthesis demonstrates a significantly increased incidence of early structural valve failure.
• This higher failure rate was not attributable to patient-specific factors or identifiable valve-related issues.
• Findings suggest a potential issue with the Trifecta valve model itself leading to premature structural deterioration.